Blue Advantage
A Medicare Approved PPO

Part B Provider-Administered Precertification Drug List

Effective November 1, 2026

Blue Cross and Blue Shield of Alabama includes the following drugs in the Blue Advantage Part B Provider-Administered Drug Precertification Program. Precertification for these provider-administered drugs is required when administered in a provider's office, outpatient facility, or home health setting. Treatments indicated as Gene Therapy/Cellular Immunotherapy (+) require precertification when administered in any place of treatment.

Abecma+
Abraxane
Actemra IV
Adakveo
Adcetris
Adstiladrin+
Aduhelm
Adzynma
Ahzantive
Akynzeo IV
Aldurazyme
Alimta
Aloxi
Alyglo
Alymsys
Amondys 45
Amtagvi
Amvuttra
Andembry
Anktiva
Aphexda
Aprepitant
Armulpeg
Arzerra
Asceniv
Aucatzyl
Avastin*
Avlayah
Avtozma
Avzivi
Bavencio
Belrapzo
Bendeka
Benlysta IV
Beovu
Beqvez
Berinert
Besponsa
Bivigam
Bizengri
Bkemv
Blenrep
Blincyto
Bortezomib
Botox
Breyanzi+
Brineura
Briumvi
Byooviz
Carvykti+
Casgevy+
Cerezyme
Cimzia
Cinqair
Cinryze
Cinvanti
Cligavyx
Columvi
Cortrophin
Cosentyx_IV
Crysvita
Cutaquig
Cuvitru
Cyramza
Danyelza
Darzalex
Darzalex Faspro
Datroway
Daxxify
Decnupaz
Durolane
Dysport
Elahere
Elaprase
Elelyso
Elevidys+
Elfabrio
Elitek
Elrexfio
Elzonris
Emend
Empliciti
Emrelis
Encelto
Enhertu
Enjaymo
Entyvio
Enzeevu
Epkinly
Epogen
Epysqli
Erbitux
Euflexxa
Evdi
Evkeeza
Evomela
Exdensur
Exondys 51
Eydenzelt
Eylea
Eylea HD
Fabrazyme
Fasenra
Faslodex
Fayuvi
Filkri
Flebogamma
Focinvez
fosaprepitant
Fulvestrant
Fusilev
Fyarro
Fylnetra
Gamifant
Gammagard
Gammagard Liquid ERC
Gammagard Liquid ERC SQ
Gammaked
Gammaplex
Gamunex-C
Gazyva
Gel-One
Gelsyn-3
Genglycos
Genvisc
Givlaari
Granix
Hemgenix+
Herceptin
Herceptin Hylecta
Hercessi
Herzuma
Hizentra
Hyalgan
Hymovis
Hyqvia
Ilaris
Ilumya
Imaavy
Imdelltra
Imfinzi
Imjudo
Imlygic
Immgolis Intri
Imuldosa
Inlexzo (Eff. 3/15/26)
Isembyld
Itvisma
Ixempra
Izervay
Jelmyto
Jemperli
Jobevne
Kadcyla
Kalbitor
Kanuma
Kebilidi
Keytruda
Keytruda qlex
Khapzory
Kimmtrak
Kisunla
Kresladi
Krystexxa
Kymriah+
Kyprolis
Lamzede
Lemtrada
Lenmeldy
Leqembi
Leqvio
Leukine
Libtayo
Loargys
Loqtorz
Lucentis
Lumizyme
Lumoxiti
Lumvoa
Lunsumio
Lunsumio Velo
Luxturna+
Lyfgenia+
Lymphir
Lynozyfic
Lytenava
Macugen
Margenza
Mepsevii
Monjuvi
Monovisc
Mylotarg
Myobloc
Naglazyme
Navitrux
Neupogen
Nexviazyme
Niktimvo
Nplate
Nucala
Nulibry
Nypozi
Nyvepria
Ocrevus
Ocrevus Zunovo
Octagam
Omalizumab-igec
Omlyclo
Omvoh
Onpattro
Ontruzant
Opdivo
Opdivo Qvantig
Opdualag
Opuviz
Orencia IV
Otulfi
Oxlumo
Paclitaxel Protein-Bound
Padcev
Panzyga
Papzimeos
Pasatru
Pavblu
Pemfexy
Pemtrexed
Pemetrexed Avyxa
Penpulimab-kcqx
Perjeta
Phesgo
Piasky
Polivy
Pombiliti
Portrazza
Poteligeo
Privigen
Procrit
Provenge
Pyzchiva
Qalsody
Qivigy
Radicava
Ranluspec
Reblozyl
Releuko

Renflexis
Retacrit
Revtorpyk
Rituxan Hycela
Rituxan IV
Rivfloza
Roctavian+
Rolvedon
Ruconest
Rybrevant
Rybrevant Faspro
Ryoncil
Rystiggo
Rytelo
Ryzneuta
Saphnelo
Sarclisa
Sarclisa Escena
Scenesse
Selarsdi
Simponi Aria
Skyrizi IV
Skysona+
Sodium Hyaluronate
Soliris
Spevigo
Spinraza
Spravato
Starjemza
Stelara IV
Steqeyma
Stimufend
Sublocade
Supartz
Sustol
Susvimo
Syfovre
Sylvant
Synojoynt
Talvey
Tecartus+
Tecelra
Tecentriq
Tecentriq Hybreza
Tecvayli
Tepezza
Testopel
Tevimbra
Tezspire
Tivdak
Tocilizumab-aazg
Tocilizumab-anoh
Tofidence
Trastuzumab-pkrb
Treanda
Tregzi
Trelstar Depot
Tremfya
Triluron
Trivisc
Trodelvy
Trogarzo
Truxima
Tudriqev
Tyenne
Tyruko
Tysabri
Tzield
Udenyca
Ultomiris
Unloxcyt
Uplizna
Ustekinumab
Ustekinumab-aauz
Ustekinumab-aekn
Ustekinumab-auub IV
Ustekinumab-srlf
Ustekinumab-stba
Ustekinumab-ttwf
Vabysmo
Vantas
Vectibix
Vegzelma
Velcade
Veopoz
Viltepso
Vimizim
Visco-3
Visudyne
Vivimusta
Vivitrol
Vpriv
Vyepti
Vyjuvek+
Vyloy
Vyondys-53
Vyvgart
Vyxeos
Vyvgart Hytrulo
Waskyra
Wezlana
Winrevair
Xembify
Xenpozyme
Xeomin
Xiaflex
Xipere
Xolair
Yartemlea
Yervoy
Yesafili
Yescarta+
Yesintek
Yimmugo
Yondelis
Zaltrap
Zanvastro
Zepzelca
Zevaskyn
Ziextenzo
Ziihera
Zimrixby
Zoladex
Zolgensma+
Zusduri
Zynlonta
Zynteglo+
Zynyz

Drug Additions

Effective January 1, 2026:
Blenrep
Eydenzelt
Qivigy
Ustekinumab-auub IV
Ustekinumab-srlf

Drug Additions

Effective February 1, 2026:
Cligavyx
Exdensur
Itvisma
Rybrevant Faspro

Drug Additions

Effective March 1, 2026:
Filkri
Lunsumio Velo
Yartemlea

Drug Additions

Effective March 15, 2026:
Inlexzo

Drug Additions

Effective May 1, 2026:
Avlayah
Kresladi
Loargys

Drug Deletion

Effective May 15, 2026:
Dextenza

Drug Additions

Effective July 1, 2026:
Decnupaz
Evdi
Immgolis Intri

Drug Additions

Effective August 1, 2026:
Aprepitant
Lumvoa
Navitrux
Ranluspec

Drug Additions

Effective September 1, 2026:
Armulpeg
Lytenava
Revtorpyk
Sarclisa Escena
Tregzi
Waskyra

Drug Additions

Effective October 1, 2026:
Genglycos
Pasatru
Tudriqev
Zimrixby

Drug Additions

Effective November 1, 2026:
Fayuvi
Isembyld
Zanvastro

*Precertification required for oncology uses only.

Product names are the property of their respective owners. This list is updated monthly and is subject to change without notice.

Online policies can be found at **AlabamaBlue.com/Providers/Policies**.

Blue Advantage® PPO is provided by Blue Cross and Blue Shield of Alabama, an independent licensee of the Blue Cross and Blue Shield Association.